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ABSTRACT 
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, 
Pantoprazole sodium were prepared by direct compression method using different 
concentration of, microcrystalline cellulose as filler, mannitol and dicalcium phosphate as 
diluents, crosscarmellose sodium as disintegrating agents, magnesium stearate and talc was 
used as a glidant and lubricant respectively. Direct compression is economic compare to wet 
granulation since it requires fewer unit operations. This means less equipment, lower power 
consumption, less space, less time and less labour leading to reduced production cost of 
tablets. The prepared tablets were evaluated for hardness, weight variation, friability and drug 
content uniformity and it was found that the results comply with official standards. The 
prepared tablets were coated using enteric coating polymer such as cellulose acetate phthalate, 
Eudragit L100 and by dip coating method. The in vitro release was studied using acidic buffer 
pH 1.2 and phosphate buffer pH 6.8. Prepared all batch’s C2F9 was found best, with hardness 
5.60 ± 0.24 (Kg/cm2), drug content 99.08 ± 0.35(%), disintegration time 7.02± 0.21(min), and 
percentage cumulative drug released which started after 120 min and reached 99.72 after 180 
min. Stability studies indicated that the developed tablets were stable and retained their 
pharmaceutical properties at room temperature and 40 °C / 75% RH for a period of 3 month.  
Key words: Pantoprazole, Direct compression, Proton pump inhibitor, Cellulose acetate 
phthalate, Eudragit L100 
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1. INTRODUCTION 
More than 50% of pharmaceutical products are orally administered for several 
reasons. This route of administration is considered as the most widely used route as it offers 
advantages like ease of administration, versatility, patient compliance and accurate dosing. 
Undesirable taste is one of the important formulation problems that are encountered with 
such oral product.  
1.1. Structure and functions of the stomach  
The stomach is continuous with the oesophagus at the cardiac sphincter and with the 
duodenum at the pyloric sphincter. It has two curvatures. The stomach is divided into three 
regions: the fundus, the body and the antrum. At the distal end of the pyloric antrum is the 
pyloric sphincter, guarding the opening between the stomach and the duodenum. When the 
stomach is inactive the pyloric sphincter is relaxed and open and when the stomach contains 
food the sphincter is closed.  
Temporary storage allowing time for the digestive, chemical digestion, preparation of 
iron for absorption, production of intrinsic factor needed for absorption of vitamin B12 in the 
terminal ileum regulation of the passage of gastric contents into the duodenum. When the 
chyme is sufficiently acidified and liquefied, the pyloric antrum forces small jets of gastric 
contents through the pyloric sphincter into the duodenum
1
.  
1.2. Acid formation  
The stomach secretes about 2.5 litres of gastric juice daily. The principal exocrine 
secretions are proenzymes such as prorennin and pepsinogen elaborated by the chief or peptic 
cells and hydrochloric acid (HCl) and intrinsic factor secreted by the parietal or oxyntic cells. 
Mucus-secreting cells abound among the surface cells of the gastric mucosa. Bicarbonate 
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ions are also secreted and are trapped in the mucus, creating a gel-like protective barrier that 
maintains the mucosal surface at a pH of 6-7 in the face of a much more acidic environment 
(pH 1-2) in the lumen
2
.  
Gastric acid secretion is a complex, continuous process in which multiple central and 
peripheral factors contribute to a common endpoint: the secretion of H+ by parietal cells. 
Neuronal (acetylcholine, ACh), paracrine (histamine), and endocrine (gastrin) factors all 
regulate acid secretion. Their specific receptors (M3, H2, and CCK2 receptors, respectively) 
are on the basolateral membrane of parietal cells in the body and fundus of the stomach. The 
H2 receptor is a GPCR that activates the Gs-adenylylcyclase-cyclic AMP-PKA pathway. 
ACh and gastrin signal through GPCRs that couple to the Gq-PLC-IP3-Ca2+ pathway in 
parietal cells. In parietal cells, the cyclic AMP and the Ca2+-dependent pathways activate 
H+,K+-ATPase (the proton pump), which exchanges hydrogen and potassium ions across the 
parietal cell membrane. This pump generates the largest known ion gradient in vertebrates, 
with an intracellular pH of about 7.3 and an intracanalicular pH of about 0.8. The most 
important structures for CNS stimulation of gastric acid secretion are the dorsal motor 
nucleus of the vagal nerve, the hypothalamus, and the solitary tract nucleus. Efferent fibers 
originating in the dorsal motor nuclei descend to the stomach via the vagus nerve and synapse 
with ganglion cells of the enteric nervous system. ACh release from postganglionic vagal 
fibers directly stimulates gastric acid secretion through muscarinic M3 receptors on the 
basolateral membrane of parietal cells. The CNS predominantly modulates the activity of the 
enteric nervous system via ACh, stimulating gastric acid secretion in response to the sight, 
smell, taste, or anticipation of food (the "cephalic" phase of acid secretion). ACh also 
indirectly affects parietal cells by increasing the release of histamine from the 
enterochromaffin-like (ECL) cells in the fundus of the stomach and of gastrin from G cells in 
the gastric antrum. ECL cells, the source of gastric histamine secretion, usually are in close 
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proximity to parietal cells. Histamine acts as a paracrine mediator, diffusing from its site of 
release to nearby parietal cells, where it activates H2 receptors. The critical role of histamine 
in gastric acid secretion is dramatically demonstrated by the efficacy of H2-receptor 
antagonists in decreasing gastric acid secretion. Gastrin, which is produced by antral G cells, 
is the most potent inducer of acid secretion. Multiple pathways stimulate gastrin release, 
including CNS activation, local distention, and chemical components of the gastric contents. 
Gastrin stimulates acid secretion indirectly by inducing the release of histamine by ECL cells; 
a direct effect on parietal cells also plays a lesser role. Somatostatin (SST), which is produced 
by antral D cells, inhibits gastric acid secretion. Acidification of the gastric luminal pH to <3 
stimulates SST release, which in turn suppresses gastrin release in a negative feedback loop. 
SST-producing cells are decreased in patients with H. pylori infection, and the consequent 
reduction of SST's inhibitory effect may contribute to excess gastrin production.  
1.3. Gastric Defenses Against Acid  
The extremely high concentration of H+ in the gastric lumen requires robust defense 
mechanisms to protect the esophagus and the stomach. The primary esophageal defense is the 
lower esophageal sphincter, which prevents reflux of acidic gastric contents into the esophagus. 
The stomach protects itself from acid damage by a number of mechanisms that require 
adequate mucosal blood flow, perhaps because of the high metabolic activity and oxygen 
requirements of the gastric mucosa. One key defense is the secretion of a mucus layer that 
protects gastric epithelial cells. Gastric mucus is soluble when secreted but quickly forms an 
insoluble gel that coats the mucosal surface of the stomach, slows ion diffusion, and prevents 
mucosal damage by macromolecules such as pepsin. Mucus production is stimulated by 
prostaglandins E2 and I2, which also directly inhibit gastric acid secretion by parietal cells. 
Thus, alcohol, aspirin, and other drugs that inhibit prostaglandin formation decrease mucus 
secretion and predispose to the development of acid-peptic disease. A second important part 
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of the normal mucosal defense is the secretion of bicarbonate ions by superficial gastric 
epithelial cells. Bicarbonate neutralizes the acid in the region of the mucosal cells, thereby 
raising pH and preventing acid-mediated damage 
3
.  
Drugs are employed with the following therapeutic aims: (1) to relieve pain; (2) to 
accelerate healing; and (3) to prevent ulcer recurrence. Therapeutic approaches are threefold: 
(a) to reduce aggressive forces by lowering H+ output; (b) to increase protective forces by 
means of mucoprotectants; and (c) to eradicate Helicobacter pylori
4
.  
 
1.4. Definition of ulcer  
Ulcers are crater-like sores (generally 1/4 inch to 3/4 inch in diameter, but sometimes 
1 to 2 inches in diameter) which form in the lining of the stomach (called gastric ulcers), just 
below the stomach at the beginning of the small intestine in the duodenum (called duodenal 
ulcers) or less commonly in the esophagus (called esophageal ulcers). In general, ulcers in the 
stomach and duodenum are referred to as peptic ulcers  An ulcer is the result of an imbalance 
between aggressive and defensive factors. On one hand, too much acid and pepsin can 
damage the stomach lining and cause ulcers. On the other hand, the damage comes first from 
some other causes, making the stomach lining susceptible to even an ordinary level of gastric 
acid
5
.  
An ulcer may arise at various locations:  
Stomach (called gastric ulcer), Duodenum (called duodenal ulcer) Oesophagus (called 
Oesophageal ulcer), Meckel's Diverticulum (called Meckel's Diverticulum ulcer)
6
.  
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1.4.1. Peptic ulcer  
A peptic ulcer, also known as ulcus pepticum, peptic ulcer disease (PUD),
7
 is an ulcer 
(defined as mucosal erosions equal to or greater than 0.5 cm) of an area of the gastrointestinal 
tract that is usually acidic and thus extremely painful. As may as 80% of ulcers are associated 
with Helicobacter pylori, a spiral-shaped bacterium that lives in the acidic environment of the 
stomach. Ulcers can also be caused or worsened by drugs such as aspirin and other non-
steroid anti-inflammatory drugs (NSAIDs)
8
. The anatomic structure of the stomach and 
duodenum ulcers is shown in Figure 1.               
 
                     
Figure 1. Structure of the stomach and duodenum ulcers 
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1.4.2. Types of peptic ulcer  
Type I: Ulcer along the lesser curve of stomach  
Type II: Two ulcers present - one gastric, one duodenal  
Type III: Prepyloric ulcer  
Type IV: Proximal gastroesophageal ulcer  
Type V: Anywhere along gastric body, NSAID induced  
 
 
1.4.3. Epidemiology  
The lifetime risk for developing a peptic ulcer is approximately 10%. In Western 
countries the prevalence of Helicobacter pylori infections roughly matches age. Prevalence is 
higher in third world countries. Transmission is by food, contaminated groundwater and 
through human saliva.  
 
1.4.4. Pathophysiology of peptic ulcer  
Classical causes of ulcers (tobacco smoking, blood groups, spices and a large array of 
strange things) are of relatively minor importance in the development of peptic ulcers. A 
major causative factor (90% of gastric and 75% of duodenal ulcers) is chronic inflammation 
due to Helicobacter pylori, a spirochete that inhabits the antral mucosa and increases gastric 
production. Gastric, in turn, stimulates the production of gastric acid by parietal cells.  
Smoking leads to, atherosclerosis and vascular spasms causing vascular insufficiency 
and promoting the development of ulcers through ischemia. A family history is often present 
in duodenal ulcers, especially when blood group O is also present. Inheritance appears to be 
unimportant in gastric ulcers
9
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1.5. Gastroesophageal reflux disease (GERD)  
It is a very common problem presenting as 'heartburn', acid eructation, sensation of 
stomach contents coming back in foodpipe, especially after a large meal, aggravated by 
stooping or lying flat. Some cases have an anatomical defect (hiatus hernia) but majority are 
only functional (LES relaxation in the absence of swallowing). Repeated reflux of acid 
gastric contents into lower one third of esophagus causes esophagitis, erosions, ulcers, pain 
on swallowing, dysphasia strictures, and increases the risk of esophageal carcinoma
10
.  
Endoscopy is used to evaluate mucosal damage from gastroesophageal reflux disease 
(GERD) and assess for the presence of Barrett’s esophagus (BE); 24-hour ambulatory pH 
testing or a therapeutic trial of a proton pump inhibitor are useful for diagnosing GERD in 
patients with persistent symptoms or atypical symptoms; manometry is useful in evaluating 
motility and before antireflux surgery. The goals of treatment of GERD are to alleviate 
symptoms, to decrease the frequency of recurrent disease, to promote healing of mucosal 
injury, and to prevent complications. Treatment of GERD involves a stepwise approach 
determined by disease severity and includes lifestyle changes and patient-directed therapy 
(Phase I); pharmacologic treatment with nonprescription and prescription medications (Phase 
II); and interventional approaches such as antireflux surgery or endoluminal therapies (Phase 
III). Patients with typical GERD symptoms should be treated with lifestyle modifications and 
a trial of empiric acid suppression therapy. Those who do not respond to empiric therapy or 
who have more complicated symptoms should undergo diagnostic tests. 
1.5.1. Epidemiology  
Gastroesophageal reflux disease occurs in both adults and children. Although 
mortality associated with GERD is rare (1 death per 100,000 patients), GERD symptoms 
have a greater impact on quality of life than do duodenal ulcers, untreated hypertension, mild 
congestive heart failure, angina, or menopause. The true prevalence and incidence of GERD 
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is difficult to assess because (a) many patients do not seek medical treatment, (b) symptoms 
do not always correlate well with severity of disease, and (c) there is no standardized 
definition or universal gold standard method for diagnosing the disease.  
 
1.5.2. Pathophysiology  
The key factor in the development of GERD is the retrograde movement of acid or 
other noxious substances from the stomach into the esophagus.9 In some cases, 
gastroesophageal reflux is associated with defective lower esophageal sphincter (LES) 
pressure or function. Patients may have decreased gastroesophageal sphincter pressures 
related to (a) spontaneous transient LES relaxations, (b) transient increases in intra-abdominal 
pressure, or (c) an atonic LES—all of which may lead to the development of 
gastroesophageal reflux. Problems with other normal mucosal defense mechanisms such as 
anatomic factors, esophageal clearance, mucosal resistance, gastric emptying, epidermal 
growth factor, and salivary buffering may also contribute to the development of GERD. 
Aggressive factors that may promote esophageal damage upon reflux into the esophagus 
include gastric acid, pepsin, bile acids, and pancreatic enzymes. Thus the composition and 
volume of the refluxate as well as duration of exposure are the most important aggressive 
factors in determining the consequences of gastroesophageal reflux. Rational therapeutic 
regimens in the treatment of gastroesophageal reflux are designed to maximize normal 
mucosal defense mechanisms and attenuate the aggressive factors
11
. 
1.6. Treatment of acid-related diseases  
1.6.1. Antacids  
Antacids are alkali preparations that neutralize hydrochloric acid in the stomach. 
Antacids can contain aluminium, magnesium, calcium or combined substances. Antacids are 
indicated for dyspepsia, GERD, reflux oesophagitis and gastritis. Their onset of action is fast, 
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but they require frequent administration (4 to 6 times a day) because of their short duration of 
action.  
 
1.6.2. H2-receptor antagonists  
Parietal cells in the stomach express receptors for acetylcholine, gastric and 
histamine. Stimulation of these receptors results in gastric acid production. H2-receptor 
antagonists (H2RAs) inhibit acid production by reversibly competing with histamine for 
binding to H2-receptors on the parietal cells. Four different H2RAs are available: cimetidine, 
famotidine, nizatidine and ranitidine. H2RAs are indicated for reflux-oesophagitis, ulcus 
duodeni, ulcus ventriculi, prevention of recurrent peptic ulcers and the treatment of NSAID 
related ulcers. These agents are primarily effective in decreasing basal acid production and 
nocturnal acid breakthrough. They are however less effective in controlling food-stimulated 
acid secretion during daytime. In general, H2RAs are administered twice a day. Although 
H2RAs have reasonable efficacy, patients develop tolerance in particular with continuous 
therapy.  
 
1.6.3. Proton pump inhibitors  
Proton pump inhibitors (PPIs) suppress gastric acid secretion by specific inhibition of 
the H+/K+- ATPase in the gastric parietal cell. This process starts with absorption of the PPI 
in the parietal cell. PPIs are weak bases, so protonation takes place in the acidic region of the 
secretory canaliculus of the parietal cell. 
PPIs are indicated for the treatment of GERD, reflux oesophagitis, peptic ulcers and 
Zollinger-Ellison syndrome. In addition, PPIs are used for gastroprotection in patients using 
NSAIDs. In combination with two suitable antibiotics, PPIs are also used for the eradication 
of H. pylori infection. In the Netherlands five PPIs are available:  
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esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole
12
.  
 
1.7. Proton pump inhibitor  
Since their introduction in the late 1980s, these efficacious acid inhibitory agents have 
rapidly assumed the major role for the treatment of acid-peptic disorders.. The mechanism of 
action of various proton pump inhibitors is shown in Figure 2. 
13
. 
 
 
Figure 2. The mechanism of action of various proton pump inhibitors 
 
1.7.1. Chemistry and pharmacokinetics  
Five proton pump inhibitors are available for clinical use: omeprazole, lansoprazole, 
rabeprazole, pantoprazole, and esomeprazole. All are substituted benzimidazoles that 
resemble H2 antagonists in structure but have a completely different mechanism of action. To 
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protect the acid-labile prodrug from rapid destruction within the gastric lumen, they are 
formulated as acid-resistant enteric-coated. After passing through the stomach into the 
alkaline intestinal lumen, the enteric coatings dissolve and the prodrug is absorbed. These 
prodrugs are lipophilic weak bases (pKa 4–5) and therefore diffuse readily across lipid 
membranes into acidified compartments (such as the parietal cell canaliculus). Within the 
acidified compartment the prodrug rapidly becomes protonated and is concentrated > 1000-
fold within the parietal cell canaliculus. There, it rapidly undergoes a molecular conversion to 
the active, reactive thiophilic sulfonamide cation. The sulfonamide reacts with the H+/K+ 
ATPase, forms a covalent disulfide linkage, and irreversibly inactivates the enzyme
14
.  
 
1.8. Tablet  
Tablets are solid dosage forms containing medicinal substances with or without 
suitable diluents. They are the most widely preferred form of medication both by 
pharmaceutical manufacturer as well as physicians and patients. They offer safe and 
convenient ways of active pharmaceutical ingredients (API) administration with excellent 
physicochemical stability in comparison to some other dosage forms, and also provide means 
of accurate dosing. They can be mass produced with robust quality controls and offer 
different branding possibilities by means of colored film coating, different shapes, sizes or 
logos. The method for the preparation of tablet is shown in Table 1. 
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Table 1.  Tablet  manufacturing methods - advantages and limitations  
 
 
Method 
  
Advantages 
 
Limitations 
Direct compression    
Simple, economical process.  
No heat or moisture, so good 
for unstable compounds  
 
 
Not suitable for all API  
Generally limited to lower 
dose compounds  
Segregation potential  
Expensive excipients  
 
Wet granulation    
Robust process suitable for 
most compounds  
Imparts flowability to a 
formulation  
Can reduce elasticity 
problems  
Coating surface with 
hydrophilic polymer can 
improve wettability  
Binds API with excipient, 
thus reducing segregation 
potential.  
 
 
Expensive: time and energy 
consuming process  
Specialized equipment  
 
required  
Stability issues for moisture 
sensitive and thermolabile 
API with aqueous 
granulation  
 
Wet granulation  
(non-aqueous)  
 
 
 
Suitable for moisture 
sensitive API  
Vacuum drying techniques 
can remove/reduce need for 
heat.  
 
 
Expensive equipment  
Needs organic facility  
Solvent recovery issues  
Health and environment 
issues  
 
Dry granulation  
(slugging or roll 
compaction)  
 
 
 
 
Eliminates exposure to 
moisture and drying  
 
 
Dusty procedure  
Not suitable for all  
 
compounds  
Slow process  
 
 
1.8.1. Types of tablets  
The tablet dosage form is a versatile drug delivery system. Different types of tablet 
formulations are available, which could be broadly classified based on: (1) route of 
administration such as tablets for oral delivery, sublingual delivery, buccal delivery, 
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rectal delivery or vaginal delivery, and (2) formulation characteristics such as immediate 
release tablets, effervescent tablets, melt-in mouth or fast dissolving tablets, delayed release 
or extended release tablets
15
.  
1.8.2. Coated tablets  
Enteric coated dosage forms, such as coated tablets, sugar-coated tablets, soft and 
hard gelatin capsules, granulates or pellets, have their firm place in the medical arsenal. The 
preparations most commonly provided with enteric coatings contain pancreatin and other 
proteolytic enzymes, diclofenac, cardiac glycosides, electrolyte preparations with sodium, 
potassium and magnesium salts as well as calcium, iron and manganese preparations. 
Bisacodyl preparations, preparations containing valproic acid as well as formulations with 
plant extract or terpenes are also common. Nowadays, enteric coatings are particularly used 
to  
 Protect active substances destroyed by the acidic gastric juice  
 Improve tolerability of medicaments irritating the stomach by only releasing them in 
the small intestine  
 Making active substances available after a time delay (sustained release),  
 Achieving targeted release and concentration in the small intestine16  
1.8.2.1 Techniques  
Generally three methods are used for tablet coating  
 Sugar coating  
 Film coating  
 Enteric coating 
 
1.8.2.1.1 Sugar coating process involves five separate operations  
 Sealing / Water proofing: provides a moisture barrier and harden the tablet surface  
 Subcoating causes a rapid buildup to round off the tablet edges  
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 Grossing/Smoothing: smoothes out the subcoated surface  
 Predetermine dimension  
 Colouring gives the tablet its color and finished size  
 Polishing produces the characteristics gloss  
 
1.8.2.1.2 Development of film coating formulations  
 If the following questions are answered then one can go for film coating:  
 Is it necessary to mask objectionable taste, color and odor  
 Is it necessary to control drug release  
 What tablets size, shape, or color constrains must be placed on the developmental 
work  
 
1.8.2.2 Materials used in film coating  
 Film formers, which may be enteric or no enteric  
 Solvents  
 Plasticizers  
 Colourants  
 Opaquant-Extenders  
 Miscellaneous coating solution components  
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1.8.2.2.1 Film formers  
Ideal requirements of film coating materials are summarized below:  
 Solubility in solvent of choice for coating preparation  
 Solubility requirement for the intended use e.g. free water-solubility, pH -dependent 
solubility  
 Capacity to produce an elegant looking product  
 High stability against heat, light, moisture, air and the substrate being coated  
 No inherent colour, taste or odor  
 High compatibility with other coating solution additives  
 Nontoxic with no pharmacological activity  
 High resistance to cracking  
 Film former should not give bridging or filling of the debossed tablet  
 Compatible to printing procedure  
 
Commonly used film formers are as follow  
 Hydroxy Propyl Methyl Cellulose (HPMC)  
 Methyl Hydroxy Ethyl Cellulose (MHEC)  
 Ethyl Cellulose (EC)  
 Hydroxy Propyl Cellulose (HPC)  
 Povidon  
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 Sodium carboxy methyl cellulose  
 Polyethylene glycols (PEG)17  
 
1.8.2.2.2 Solvents  
Solvents are used to dissolve or disperse the polymers and other additives and convey 
them to substrate surface.  
Ideal requirement of solvents used for enteric coatings are summarized below  
 
 Should be either dissolve/disperse polymer system  
 Should easily disperse other additives into solvent system  
 Small concentration of polymers (2-10%) should not in an extremely viscous solution  
 Should be colorless, tasteless, odorless, inexpensive, inert, nontoxic and 
nonflammable.  
 Rapid drying rate  
 No environmental pollution  
 
1.8.2.2.3 Plasticizers  
Phthalate esters , Phosphate esters, Stearates, Sebacate.  
 
1.8.2.2.4 Colorants  
1.8.2.3 Ideal properties of enteric coating material are summarized as below  
 Resistance to gastric fluids  
 Susceptible/permeable to intestinal fluid  
 Compatibility with most coating solution components and the drug substrate  
 Formation of continuous film  
Chapter 1                                                                                    Introduction 
 
Dept.of Pharmaceutics                                                  17                    J.K.K.Nattaraja college of  Pharmacy 
 
 Nontoxic, cheap and ease of application  
 Ability to be readily printed  
 
Polymers used for enteric coating are as follow  
 Cellulose acetate phthalate (CAP)  
 Acrylate polymers  
 Hydroxy propyl methyl cellulose phthalate  
 Polyvinyl acetate phthalate  
 
1.8.2.4 New materials used for tablet coating
18
  
 Zein  
 Aqua-Zein®, which is an aqueous zein formulation containing no alcohol  
 Amylose starch and starch derivatives  
 Dextrins  
 
1.9 Directly compression  
The International Pharmaceutical Excipients Council (IPEC) defines excipients as 
"Substances, other than the Active Pharmaceutical Ingredient (API) in finished dosage form, 
which have been appropriately evaluated for safety and are included in a drug delivery 
system to either aid the processing or to aid manufacture, protect, support, enhance stability, 
bioavailability or patient acceptability, assist in product identification, or enhance any other 
attributes of the overall safety and effectiveness of the drug delivery system during storage or 
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use". Solvents used for the production of a dosage form but not contained in the final product 
are considered to be excipients, i.e. the granulation fluids, which might be dried off later, 
should comply with relevant requirements of Pharmacopoeia unless adequately justified. 
Excipients no longer maintain the initial concept of "inactive support" because of the 
influence they have both over biopharmaceutical aspects and technological factors. The 
desired activity, the excipients equivalent of the active ingredient's efficacy, is called its 
Functionality19. Figure 3 indicating the direct compression process of tablet manufacturing20 and 
Table 2 shows the ideal requirements, advantages and limitations of direct compression. 
 
 
Figure 3. The direct compression process of tablet manufacturing 
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Table 2. Ideal requirements, advantages and limitations of direct compression 
 
 
 
1.9.1 Advantages of direct compression  
 Direct compression is economic compare to wet granulation since it requires fewer 
unit operations. This means less equipment, lower power consumption, less space, 
less time and less labour leading to reduced production cost of tablets  
 More suitable for moisture and heat sensitive APIs, since it eliminates wetting and 
drying steps and increases the stability of active ingredients by reducing detrimental 
effects  
 Changes in dissolution profiles are less likely to occur in tablets made by direct 
compression on storage than in those made from granulations. This is extremely 
important because the official compendium now requires dissolution specifications in 
most solid dosage forms  
Ideal requirement  Advantage  Limitation  
Flowability  Cost effective 
production  
Segregation  
Compressibility  Better stability of API  Variation in 
functionality  
Dilution potentia  Faster dissolution  Low dilution potential  
Rework ability  Less wear and tear of 
punches  
Rework ability  
Stability  Simplified validation  Poor compressibility of 
API  
   
Controlled particle 
size  
Lower microbial 
contamination  
Lubricant sensitivity  
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 Disintegration or dissolution is the rate-limiting step in absorption in the case of 
tablets of poorly soluble API prepared by wet granulation. The tablets prepared by 
direct compression disintegrate into API particles instead of granules that directly 
come into contact with dissolution  
 The high compaction pressure involved in the production of tablets by slugging or 
roller compaction can be avoided by adopting direct compression  
 The chances of wear and tear of punches and dies are less21-22  
1.9.2 Factors in formulation development  
Many factors influence the choice of the optimum direct-compression filler to be used 
in a tablet formulation.  
More than in any other type of tablets, successful formulations of direct compression 
tablets depend on careful consideration of excipient properties and optimization of the 
compressibility, fluidity, and lubricability of powder blends. The importance of standardizing 
the functional properties of the component raw materials and the blending parameters cannot 
be overstressed. Preformulation studies are essential in direct-compression tableting even for 
what would appear to be a simple formulation
23
. 
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2. AIM & OBJECTIVE OF WORK 
The tablet enteric coating is perhaps one of the oldest pharmaceutical processes still in 
existence. Enteric refers to the small intestine; therefore enteric coatings prevent release of 
medication before it reaches the small intestine.  
Enteric-coated dosage forms do not release the active ingredient until they have been 
transported down to the neutral reacting part of the small intestine; hence they offer the best 
possibilities for the protection of unstable drugs at low pH values. The most important 
reasons for enteric coating can be summarized as follows: - to protect acid-labile drugs from 
gastric fluid (e.g. enzymes and certain antibiotics), - to prevent gastric distress or nausea due 
to irritation from a drug (e.g. sodium salicylate), - to deliver drugs intended for local action in 
the intestines (e.g. intestinal antiseptics could be delivered to their site of action in a 
concentrated form and bypass systemic absorption in the stomach), - to deliver drugs that are 
optimally absorbed in the small intestine to their primary absorption site in their most 
concentrated form, - to provide a delayed-release component for repeat action .  
The modified enteric-coated Pantoprazole sodium formulation that provide immediate 
release in the small intestine and simultaneously provide sustained input of drugs that have an 
absorption window and at the same time may improve or maintain bioavailability of the 
formulation.  
The most potent suppressors of gastric acid secretion are inhibitors of the gastric H+, 
K+-ATPase (proton pump). In typical doses, these drugs diminish the daily production of 
acid (basal and stimulated) by 80% to 95%. Available PPI’s for clinical use: Omeprazole, 
esomeprazole, lansoprazole, pantoprazole, rabeprazole. 
The primary treatment goal patients with peptic ulcer and GERD are relief of 
symptoms, prevention of complications related to the disease and healing of ulceration. 
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Pantoprazole is a substituted benzimidazole derivative that targets gastric acid proton pumps 
,the final common pathway for gastric acid secretion. The drug covalently binding to the 
proton pumps, causing prolonged inhibition of gastric acidsecretion. But the drug causes 
irritation to gastric mucosa which may lead to nausea and vomiting. The stability of 
pantoprazole is rapidly degrades in acid medium of the stomach, but has acceptable stability 
in alkaline conditions. Therefore, pantoprazole should be delivered into the intestine. Hence, 
formulation of pantoprazole as an enteric coated tablet may solve the stability problem of 
drug in the stomach and release the drug in the intestine.  
The main objectives of the present study was  
 To formulate and evaluate enteric coated tablets Pantoprazole sodium by direct 
compression method  
 Selection of suitable coating material to develop the dosage form  
 To overcome the drug degradation by the gastric enzymes as well as the acidic 
environment of the stomach  
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3.PLAN OF THE WORK 
1.Pre-compression parameters 
 Bulk density  
 Tapped density 
 Carr’s index 
 Haussner ratio 
 Angle of repose 
2. Formulation of core tablets, by direct compression 
3. Post compression parameters  
 Weight variation  
 Hardness test 
 Friability test 
 Drug content 
 Disintegration time 
4. Tablets coating  
 Filmthickness 
 Film solubility 
 In-vitro dissolution studies 
5. Stability studies  
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4. DRUG AND EXCIPIENTS PROFILE 
 
4.1 PANTOPRAZOLE
24, 25, 26
 
Chemistry:                      Chemically, pantoprazole sodium sesquihydrate, is a sodium 
5- (difluoromethoxy)-2[[(3,4,dimethoxy-2pyridinyl)methyl] 
sulfinyl] -1H benzimidazole sesquihydrate. 
Molecular formula:       C16H15F2N3O4S. 1.5 H2O 
Molecular weight:           432.4 gm/mol. 
 
 
 
Mechanism of action: Pantoprazole is a proton pump inhibitor (PPI) that suppresses 
the final step in gastric acid production by covalently 
binding to  the  (H
+
,K
+
)  -  ATPase  enzyme  system  at  the  
secretory surface  of  the   gastric   parietal   cell.   This  effect  
leads  to inhibition of both  basal  and  stimulated  gastric  
acid secretion irrespective  of  the  stimulus.  The binding to 
the (H
+
, K
+
)- ATPase results in a duration of antisecretory 
effect that persists longer than 24 h for all doses tested. 
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Pharmacokinetics: Pantoprazole sodium is prepared as an enteric-coated tablet so                      
that absorption of  pantoprazole begins   only   after t h e   tablet area 
under the serum concentration time curve (AUC) increase in a manner 
proportional to oral and intravenous doses from 10 mg to 80 mg. 
Pantoprazole does not accumulate and its pharmacokinetics are 
unaltered with multiple daily dosing.  
Absorption:  The absorption of pantoprazole is rapid, with a Cmax of 2.5 μg/ml that 
occurs approximately 2.5 h after administration of a single or multiple 
oral 40 mg doses of pantoprazole sodium delayed release tablets. 
Pantoprazole is well absorbed; it undergoes little first-pass metabolism 
resulting in an absolute bioavailability of approximately 77%. 
Administration with food may delay its absorption.  
Distribution:  The apparent volume of distribution of pantoprazole is approximately 
11.0 to 23.6L, distributing mainly in extracellular fluid. The serum 
protein binding of pantoprazole is about 98%, primarily to albumin.  
Metabolism:  Pantoprazole is extensively metabolized in the liver through the 
cytochrome P450 (CYP) system. Pantoprazole metabolism is 
independent of the route of administration (intravenous or oral).  
Elimination:  After a single oral or intravenous dose of pantoprazole to healthy, 
normal metabolizer volunteers, approximately 71% of the dose was 
excreted in the urine with 18% excreted in the feces through biliary 
excretion. 
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Drug-drug interactions: Pantoprazole given with atazanavir, indinavir, nelfinavir may be 
reduce the plasma concentrations. Coadministration with atazanavir is 
not recommended. Plasma levels of certain azole antifungal (e.g. 
itraconazole, ketoconazole) may be reduced, avoid this combination if 
possible.  
Contraindications: Pantoprazole sodium delayed-release tablets are contraindicated in 
patients with known hypersensitivity to any component of the 
formulation. 
 Precautions:  Generally, daily treatment with any acid-suppressing medications over 
a long period of time (eg, longer than 3 years) may lead to 
malabsorption of cyanocobalamin (vitamin B-12).  
Side effects:  The common side effects are abdominal pain, blurred vision, dry 
mouth, fatigue, flushed, dry skin, increased hunger, increased thirst, 
increased urination, nausea, sweating.  
Uses:  Pantoprazole is used to treat erosive esophagitis or "heartburn" caused 
by gastroesophageal reflux disease (GERD). Pantoprazole may also be 
used to treat Zollinger- Ellison syndrome, stomach produces too much 
acid.  
Dose:  It is administered orally dose of 40 mg once daily. 
 Storage:  Store the medicine in a closed container at room temperature, away 
from heat, moisture, and direct light. 
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4.2MICROCRYSTALLINE CELLULOSE
27
  
Non-proprietary names: Cellulosum microcristallinum, microcrystalline cellulose 
Synonyms:    Avicel, Emcocel and Tabulose, Crystalline cellulose  
Chemical Name:   Cellulose  
Empirical formula:   (C6H10O5) n, Where n=220  
Molecular weight:   Approximately 36,000  
Description:    white, odorless, tasteless, crystalline powder 
Functional category:  Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrant.  
Solubility:  Slightly soluble in 5% w/v sodium hydroxide solution; 
practically insoluble in water, dilute acids, and most organic 
solvents. 
Applications:  Adsorbent-20 to 90%, Antiadherent–5 to 20%, Capsule 
binder/diluents -20 to90%, Tablet disintegrant-5 to 15%, Tablet 
binder/diluents-20 to 90%. 
Stability and Storage Conditions:  Microcrystalline cellulose is a stable though 
hygroscopic           material. The bulk material should be stored 
in a well-closed container in a cool, dry place.  
Incompatibilities: Incompatible with strong oxidizing agents.  
Safety:  It is not absorbed systemically following oral administration 
and thus has little toxic potential. 
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4.3 MAGNESIUM STEARATE
27
  
Non-proprietary names:   Magnesium stearate, Magnesii stearas. 
Synonyms:  Magnesium octadecanoate; octadecanoic acid, 
magnesium salt; stearic acid, magnesium salt 
 Chemical Name:    Octadecanoic acid magnesium salt 
 Empirical formula:    C36H70MgO4  
Molecular weight:    591.34  
Description:  Magnesium stearate is a very fine, light white, 
precipitated or milled, impalpable powder of low bulk 
density, having a faint odor of stearic acid and a 
characteristic taste. 
Functional category:    Tablet and capsule lubricant. 
Solubility:  Practically insoluble in ethanol, ethanol (95%), ether 
and water; slightly soluble in warm benzene and warm 
ethanol. 
Applications:  It is primarily used as a lubricant in capsule and tablet 
manufacture at concentrations between 0.25% and 5.0% 
w/w. It is also used in barrier creams. 
 Stability and Storage Conditions: Magnesium stearate is stable and should be stored in a 
well closed container in a cool, dry place.  
Incompatibilities:    Incompatible with strong acids, alkalis, and iron salts.  
Safety:  Oral consumption produce a laxative effect. No toxicity 
information is available. 
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4.4 TALC
27
  
Non-proprietary  
names:     Purified talc, Talc, Talcum.  
Synonyms:     Altalc, hydrous magnesium calcium silicate.  
Chemical Name:    Talc  
Structural formula:    Mg6(Si2O5)4(OH)4  
Description:  Talc is a very fine, white to greyish-white, odorless, 
impalpable unctuous, crystalline powder. 
Functional category:  Anticaking agent; glidant diluent; tablet and capsule 
lubricant.  
Solubility:  practically insoluble in dilute acids and alkalis, organic 
solvents, and water. 
 Applications:  Talc was once widely used in oral solid dosage 
formulations as a lubricant, diluent and lubricant.  
Stability and Storage Conditions:Talc is a stable material and may be sterilized by heating 
at 160 ºC for not less than 1 hour. Talc should be stored 
in a well-closed container in a cool, dry place. 
 Incompatibilities:    Incompatible with quaternary ammonium compounds.  
Safety:  Talc is not absorbed systemically following oral 
ingestion and is therefore regarded as an essentially 
nontoxic material. However intranasal or intravenous 
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abuse of products containing talc can cause granulomas 
in body tissues. 
4.5 CROSCARMELLOSE SODIUM
27
  
Synonyms:    Ac-Di-Sol; Cross-linked carboxymethyl cellulose sodium;  
Description:    It occurs as white, odourless powder.  
Functional categories  Tablet and capsule disintegrate.  
Solubility:  Insoluble in water, but rapidly swells to 4-8 times its original 
volume on contact with water. Practically insoluble in acetone, 
ethanol and toluene.  
Stability and storage:  Croscarmellose sodium is stable, though it is a hygroscopic 
material. It should be stored in airtight container in a cool and 
dry place.  
Safety:  It is nontoxic and non-irritant material and widely used in oral 
pharmaceuticals. 
Application: It is used in oral pharmaceutical formulations as a disintegrate 
for capsules and tablets. In tablet formulations, croscarmellose 
sodium may be used in both direct-compression and wet-
granulation processes. Croscarmellose sodium at concentrations 
up to 5% w/w may be used as a tablet disintegrant, although 
normally 2% w/w is used in tablets prepared by direct 
compression and 3% w/w in tablets prepared by a wet-
granulation process.  
Incompatibilities:  Not compatible with strong acids. Drug and Excipients Profile 
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4.6 MANNITOL
27
  
Non proprietary name:  Mannitol, D-Mannitol ,Mannitolum  
Synonyms:  Cordycepic acid; C*PharmMannidex; E421; manna sugar; 
 Chemical name:  D-Mannitol  
Category:  Diluents, diluents for lyophilized preparations; sweetening 
agent; tablet and capsule diluent; tonicity agent. 
 Description:  Mannitol occurs as white, odourless, crystalline powder, or 
free-flowing granules. It has a sweet taste, approximately as 
sweet as glucose and half as sweet as sucrose. 
 Solubility:  Soluble in water, alkalies, ethanol, glycerine and propane. 
 Stability and storage:  Mannitol is stable in the dry state and in aqueous solutions. 
Solutions may be sterilized by filtration or by autoclaving and 
if necessary may be autoclaved repeatedly with no adverse 
physical or chemical effects.  
Safety:  Mannitol is a naturally occurring sugar alcohol found in 
animals and plants; it is present in small quantities in almost all 
vegetables. Laxative effects may occur if mannitol is consumed 
orally in large quantities. If it is used in foods as a bodying 
agent and daily ingestion of over 20 g is foreseeable, the 
product label should bear the statement ‘excessive consumption 
may have a laxative effect. 
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4.7 CELLULOSE ACETATE PHTHALATE
27
 
 Nonproprietary names:  Cellacephate; Cellacefate  
Synonyms:  CAP, Cellulose acetophthalate  
Chemical name:  Cellulose, acetate, 1,2-benzenedicarboxylate.  
Category:  Pharmaceutical aid (for enteric coating of tablets).  
Description:  White, free-flowing powder or colorless flakes; odorless or 
with a faint odor of acetic acid; hygroscopic.  
Solubility:  Freely soluble in acetone; soluble in diethylene glycol and in 
dioxan; practically insoluble in water, in ethanol (95%), in 
toluene and in chlorinated and non chlorinated aliphatic 
hydrocarbons. It dissolves in dilute solutions of alkalis.  
Storage:  To be stored in tightly-closed containers at a temperature 
between 8° and 15 °C.  
Viscosity:  50-90 cps good coating solution with a honey like consistency, 
but the viscosity is influenced by the purity of the solvent.  
Applications:  CAP is used as an enteric coating material for tablets or 
capsules.  
Incompatibilities:  Cellulose acetate phthalate is incompatible with ferrous sulfate, 
ferric chloride, silver nitrate, sodium citrate, aluminum sulfate, 
calcium chloride, mercuric chloride, barium nitrate, acetate, 
and strong oxidizing agents such as strong alkalis and acids. 
 
 
 
 
Chapter 4                                                                                          Drug and excipients profile 
 
Dept.of  Pharmaceutics                                   33                 J.K.K.Nattaraja college of  Pharmacy 
 
4.8 EUDRAGIT L-100 27 
 Synonyms:   Methacrylic acid 
 Functional category:   Film former, tablet binder  
Description:   White powders with a faint characteristic odor.  
Solubility:  1 gm of Eudragit L-100 dissolves in 7 g methanol, 
ethanol, in aqueous isopropyl alcohol and acetone. 
Insoluble in ethyl acetate, methylene chloride, petroleum 
ether and water.  
Stability and storage conditions:  Eudragit and L 100 polymers are stable at room 
temperature.  
Safety:  Acute toxicity studies have been performed in rats, rabbits 
and dogs. No toxic effects were observed. Chronic toxicity 
studies were performed in rats over a period of 3 months. 
No significant changes were found in the animal organs.  
Applications:  Eudragit L 100 and S 100 are employed as film coating 
agents resistant to gastric fluid with solubility above pH 
6.0 and pH 7.0 respectively, for enteric coating of 
formulations. Eudragit L and S, also referred to as 
methacrylic acid copolymers in the USP32–NF27 
monograph, are anionic copolymerization products of 
methacrylic acid and methyl methacrylate. The ratio of 
free carboxyl groups to the ester is approximately 1 : 1 in 
Eudragit L (Type A) and approximately 1 : 2 in Eudragit S 
(Type B). 
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4.9 CALCIUM PHOSPHATE
27
  
Nonproprietary Names:  Anhydrous Calcium Hydrogen Phosphate, Anhydrous 
Dibasic Calcium Phosphate 
 Chemical Name:    Dibasic calcium phosphate  
Molecular Weigh:    136.06 
Functional Category:   Tablet and capsule diluent.  
Applications: Anhydrous dibasic calcium phosphate is used both as an 
excipient and as a source of calcium in nutritional 
supplements. It is used particularly in the 
nutritional/health food sectors. It is also used in 
pharmaceutical products because of its compaction 
properties, and the good flow properties of the coarse-
grade material. 
Description: Anhydrous dibasic calcium phosphate is a white, 
odorless, tasteless powder or crystalline solid. It occurs 
as triclinic crystals.  
Stability and Storage Conditions: Dibasic calcium phosphate anhydrous is a 
nonhygroscopic, relatively stable material. Under 
conditions of high humidity it does not hydrate to form 
the dihydrate.  
Incompatibilities:  Dibasic calcium phosphate should not be used to 
formulate tetracyline antibiotics. 
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5. REVIEW OF LITERETURE 
Sumit et al (2009)., formulated pantoprazole enteric coated tablets, in aqueous media 
more acidic than pH 4 it suffers a practically complete decomposition within a period shorter 
than 10 minutes. Even in solid state it is sensitive to heat, humidity, light and especially to 
substances containing an acidic group. Pantoprazole which have an irritant effect on the 
stomach, can be coated with a substance that will only dissolve in the small intestine, hence 
such types of drugs, enteric coating added to the formulation tends to avoid the stomach's 
acidic exposure, delivering them instead to a basic pH environment (intestines pH 5.5 and 
above) where they do not degrade, and give their desired action. This stimulate us to 
formulate and evaluate pantoprazole as an enteric coated tablet
28
.  
Anroop et al (2010)., developed and evaluated enteric coated tablets for esomeprazole 
magnesium trihydrate, with different enteric coating was carried out using different polymers 
like Eudragit L-30 D-55, hydroxy propyl methylcellulose phthalate, cellulose acetate 
phthalate and Acryl-EZE® to achieve 5% weight gain. Disintegration studies showed that the 
formulations failed in 0.1 N HCl media. Hence the quantity of enteric coating was increased 
to 8% w/w. In vitro analysis of the developed tablets was carried out. Results from 
disintegration time and dissolution rate studies indicate that all the esomeprazole enteric 
tablets prepared possess good integrity, desirable for enteric coated tablets. Among the 
polymers studied, the methacrylic polymers exhibited better dissolution rate than the 
cellulose polymers. Therefore stability studies indicate that the prepared formulations were 
stable for a period of three months. This study concluded that enteric coated tablets of 
esomeprazole can be prepared using any of the enteric coating polymer studied using a 
minimal weight gain of 8%
29
. 
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Saffar et al (2007)., studied on in vitro evaluations (hardness, friability, weight 
variation, assay, disintegration and dissolution tests) of marketed pantaprazole tablets (2 
batches of each) from WHO GMP certified Nepalese companies ,non-GMP certified 
Nepalese companies and multinational companies were done. The result of hardness, 
friability, weight variation, and assay and disintegration tests of all marketed products comply 
with pharmacopoeial limit. However, BP-02-A2 showed the fastest disintegration. Moreover, 
the comparison of percentage drug release of these companies on the basis of dissolution 
study demonstrated that BP-02-A2 (90 % drug release) complied best with standard RDRL 
protocol while BP-02-B2 (78% drug release) does not comply with above specification
30
.  
Chanchal et al (2011)., made an attempt to perform various prototype trials were 
taken and evaluated with respect to the various quality parameters such as disintegration, 
tablet weight, thickness; diameter, gastric resistance test, drug uniformity and dissolution also 
determine optimum polymer concentration for enteric coating. Pantoprazole enteric coated 
tablets prepared by direct compression. Because of its instability in acidic environment 
decided to give it alkaline environment with the help of alkaliser and also protective seal 
coating between core tablet and acid resistant enteric coat. The primary aim of using delayed 
release is to protect the drug from an unfavorable environment in the gastrointestinal tract, to 
protect the gastrointestinal tract from high, local concentrations of an irritating drug 
compound, or to target a specific region of absorption or action
31
.  
Putta et al (2011)., prepared directly compressible esomeprazole magnesium 
trihydrate enteric coated tablets to deliver drug in upper GIT. Different tablets were prepared 
with super disintegrates like Ac-Di-Sol, Crospovidone, sodium starch glycolate and diluents 
like Pharmatose DCL11, Mannogem EZ. Tablets were enteric coated using Acryl-EZE. The 
tablets were evaluated for hardness, disintegration time and in vitro drug release. The powder 
bed showed good rheological properties and enteric coated tablets showed acid uptake value 
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<5 indicates significant protection of acid liable drug. The compressional parameters were 
within the limits, the drug content in all formulations was found to be uniform and consistent. 
In vitro dissolution studies indicated there is no drug loss during gastric phase
32
. 
 Bozdag et al (1999)., studied omeprazole, , is a specific and noncompetitive inhibitor 
of the enzyme H+/K+-ATPase, known as the gastric proton pump. It is unstable in conditions 
of low pH and must be protected from the effects of gastric acid when given orally; thus, it is 
administered in the form of enteric-coated dosage/arms. In this present study, various coating 
solutions were prepared in different concentrations and appliedto previously subcoated 
omeprazole tablets to examine whether this coating prevented omeprazolefrom degrading in 
acidic media. Dissolution tests were conducted in acidic and basic media to determine the 
appropriate coating ratio. For stability evaluation, an accelerated stability test was performed 
on developed tablet formulations and commercially obtained capsules
33
.  
Mohamed et al (2009)., evaluated the bioequivalence of two commonly prescribed 
enteric coated formulations of 20 mg omeprazole, Omez (test) and Losec (reference). In vitro 
studies were adopted to determine and compare the dissolution behavior of both products. 
Both brands met the requirements specified by the United States pharmacopoeia for 
omeprazole delayed release capsules. In vivo study was conducted according to a single dose, 
standard two-way, crossover design with a washout period of one week. Twelve healthy adult 
Egyptian male volunteers were randomly allocated to receive a single 20 mg dose of either 
test or reference product. Blood samples were collected at specified time intervals, plasma 
was separated and analyzed for omeprazole concentration using an HPLC assay
34
.  
Devraj et al (2010)., studied time released drug delivery of metronidazole. 
Metronidazole containing matrix tablets coated with 3,4,5 & 6% w/v cellulose acetate 
phthalate in acetone were examined for applicability as timed release tablets with a 
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predetermined lag time of 4-5 hrs. Different types of enteric coated tablets were prepared and 
there drug dissolution profile was studied in 0.1 N HCl (0 to 2hr) and PBS 6.8 (2- 24 hr) as 
dissolution media at 37±0.5 ºC,100 rpm by USP Apparatus-1(Basket assembly). The result 
indicated that the tablets with timed release functions could be prepared and, that the lag time 
were increased as the coat concentrations increased (3% to 6%w/v).The different kinds of 
timed release enteric coated tablets that showed lag time of 2 to 5.4 hrs in in- vitro dissolution 
in 2% w/v rat caecal\ content in 6.8 PBS(Phosphate buffer saline). The lag time showed a 
good agreement between the in- vitro test in PBS 6.8 and in -vitro test in 2% w/v rat caecal 
content. However the lag times were 4.5 hrs in in-vitro test in 2%w/v rat caecal content 
medium
35
. 
Dhruba et al (2010)., made an attempt to decrease dosing frequency by prepare a 
mucoadhesive tablets. Various hydrophilic polymers such as HPMC, Sodium alginate, 
Tragacanth, Sodium CMC and hydrophobic polymer EC are used to prepare mucoadhesive 
tablets and EC is use for enteric coating were subjected to friability, content uniformity, 
surface pH, wash-off test and dissolution study. The results of friability tests carried out for 
all the formulations are within the official limit and acceptable. According to in vitro drug 
release study the formulation containing HPMC (81.17897%) before coating and (68.93494% 
after coating with ethyl cellulose), ethyl cellulose (83.91042% before coating and 51.06213% 
after coating with ethyl cellulose) and tragacanth (83.75215% before coating and 73.24184% 
after coating with ethyl cellulose) gives better result than the other formulation. Among these 
three formulations, the formulation containing ethyl cellulose gives better result
36
.  
Durriya et al (2009)., reviewed that, tablet coating is perhaps one of the oldest 
pharmaceutical processes still in existence. It offers many benefits namely: improving the 
aesthetic qualities of the dosage form, masking unpleasant odour or taste, easing ingestion, 
improving product stability and modifying the release characteristics of the drug. It is widely 
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used in enteric coating, controlled release system and osmotic pump systems. Enteric coated 
dosage forms are designed to resist the destructive action of the gastric fluid and to 
disintegrate in the higher pH environment of the intestinal fluid. Polymer for enteric coating 
can be applied to solid dosage forms (i.e. granules, pellets, or tablets) from aqueous solutions 
of alkali salts, or organic solvent solutions. The most commonly used pH sensitive enteric 
coating polymers today include: cellulose acetate phthalate (CAP), cellulose acetate 
trimellitate (CAT), hydroxypropyl methyl cellulose phthalate (HPMCP) and methacrylic acid 
copolymers. In recent years, acrylic copolymers have evolved as the most preferred materials 
for designing enteric coating formulations in terms of performance and global acceptability
37
.  
Senthil et al (2010)., developed enteric coated tablets of didanosine by wet 
granulation technique using polymer Ethyl Cellulose std 100 FP, Ethyl Cellulose Med 70 P, 
Ethyl Cellulose Med 50 P and other excipients are povidone micro crystalline cellulose in 
different ratios. These polymers and excipients are used for sustained the drug release. And 
20% solution of Eudragit L 100 with Iso propyl alcohol used for enteric coat. And Di Ethyl 
Phthalate added as polishing agent in enteric coat solution. Tablets were evaluated for 
physical characteristics, weight variation, hardness, drug content, and further tablets were 
evaluated for in vitro drug release for 12 hrs i.e. first 2 hrs no drug release was observed and 
gradually drug release was increased up to 12 hrs by using Ethyl Cellulose std 100 P 20% 
with other excipients
38
.  
Muhammad et al (2011)., studied direct compression is the simplest and most 
economical method f or the manufacturing of tablets because it requires less processing steps 
than other techniques. In early 1960’s, the introduction of spray dried lactose (1960) and 
Avicel (1964) had changed the tablet manufacturing process and opened avenues of direct 
compression tableting. The simplicity of the direct compression process is apparent from a 
comparison of the steps involved in the manufacture of tablets by wet granulation, roller 
Chapter 5                                                                                                      Review of litereture 
 
Dept.of Pharmaceutics                             40                          J.K.K.Nattaraja college of  Pharmacy 
 
compaction and direct compression techniques . It has been estimated that less than 20 
percent of pharmaceutical materials can be compressed directly into tablets due to lack of 
flow, cohesion properties and lubrication. Therefore, they must be blended with other directly 
compressible ingredients to manufacture satisfactory tablets
39
.  
Vivek et al (2011)., studied enteric coated tablets of didanosine using different 
polymers as release retarding agent to overcome the gastric juice incompatibility. 
Preformualtion study was done initially and results directed for the further course of 
formulation . Based on preformualtion studies different formulation batches of didanosine 
was prepared using selected excipient. Granules were evaluated for tests loss on drying , bulk 
density , tapped density, compressibility index, hausner ratio. Tablets were tested for weight 
variation, thickness, hardness, friability and in vitro drug release as per official procedure. 
Change in dissolution parameter study made it suitable for minute physiological variables
40
.  
Singh et al (2009)., made an attempt to formulate a delayed release solid dosage 
forms. Prepared the conventional diclofenac sodium tablets by wet granulation method (non-
aqueous) using granulating fluid (isopropyl alcohol). Developed the aqueous coating formula 
using shacryl and non-aqueous coating formula using HPMCP and optimized the best 
aqueous coating formula. Coating was performed in a mini coating pan at 107 rpm using low-
pressure air atomized liquid spray techniques. Comparative dissolution, disintegration and 
antiulcer studies were performed on the best products and marketed products. The 
Comparative antiulcer studies were performed on wister albino rats using conventional, 
dummy and enteric-coated tablets
41
.  
Rupesh et al (2010)., prepared enteric coated tablets of Ketorolac Tromethamine by 
direct compression method using EudragitL100 as coating polymer. In vitro release profiles 
of batches F1-F4 shows that Ketorolac Tromethamine in drug :polymer ratio with Guar gum, 
Chapter 5                                                                                                      Review of litereture 
 
Dept.of Pharmaceutics                             41                          J.K.K.Nattaraja college of  Pharmacy 
 
Xanthan Gum, Ethyl cellulose and Sodium alginate give 79.32%, 91.52%, 88.35% and 
92.19% drug release respectively in 12 hours. In vitro release profile of batches F5-F8 shows 
that Ketorolac Tromethamine in ratio 1:4 with Guar gum, Xanthan Gum, Ethyl cellulose and 
Sodium alginate gives release of 85.21%, 95.52%, 93.50%, 97.24% respectively in 12 hours. 
In vitro release profile of batches F9-F12 shows that Ketorolac Tromethamine in ratio 1:3 
with Guar gum, Xanthan Gum, Ethyl cellulose and Sodium alginate gives release of 89.50%, 
98.25%, 95.22%, 100.27% respectively in 12 hours
42
.  
Rabia et al (2010)., developed enteric coated ibuprofen tablets in order to avoid 
gastric mucosal irritation, diffusion of drug across mucosal lining and to let active ingredient 
be absorbed easily in small intestine. The formulation was developed and manufactured 
through the direct compression process, the simplest, easiest and most economical method of 
manufacturing. Enteric coating was done using an Opadry white subcoating and an aqueous 
coating dispersion of Acryl-Eze. Enteric coated formulation was subjected to disintegration 
and dissolution tests by placing in 0.1 M hydrochloric acid for 2 h and then 1 h in phosphate 
buffer with a pH of 6.8. About 0.04% of drug was released in the acidic phase and 99.05% in 
the basic medium. These results reflect that ibuprofen can be successfully enteric coated in 
order to prevent its release in the stomach and facilitate rapid release of the drug in the 
duodenum, due to the presence of superdisintegrant. Formulating this enteric coated tablets 
could increase patient compliance by decreasing adverse drug reactions (ADRS) associated 
with Ibuprofen therapy
43
.  
Mominurl et al (2010)., formulated diclofenac sodium (DS) microspheres with two 
different polymers, ethyl cellulose (EC) and cellulose acetate phthalate (CAP). 
Emulsification-solvent evaporation method was used to prepare the microspheres. Liquid 
paraffin containing 1.5% (w/w) span 80 was the external phase and acetone-polymer solution 
was the internal phase. EC and CAP, both as single and as mixture, were used to encapsulate 
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DS. EC microspheres were more spherical in shape and showed more entrapment efficiency 
than CAP microspheres. The size of the microspheres varied between 560-920 μm and as 
high as 90% loading efficiency was obtained. In vitro release study was carried out in 0.1 N 
hydrochloric acid solution (pH 1.2) for first 2 hours followed by in phosphate buffer solution 
(pH 6.8) for next 4 hours. After first 2 hours of dissolution in 0.1 N hydrochloric acid, EC 
microspheres released 24% of DS whereas CAP microspheres released only 2% DS. After 4 
hours of dissolution in phosphate buffer, 60% DS was released from EC microspheres and 
almost all drug was released from CAP microspheres. Combination of EC and CAP showed 
more sustaining action than the individual polymer in both the dissolution media. DS release 
from EC microspheres followed Higuchi model whereas CAP microspheres followed first 
order model
44
.  
Rakesh et al (2012)., prepared enteric-coated drug multiparticulates with single 
polymeric coatings (acrylic or cellulosic) were compared with two different polymeric layer 
coatings to evaluate the effectiveness of latter coatings in more effectively producing a better 
rabeprazole sodium delayed-release pellet product The pH-dependent, enteric acrylic, and 
cellulosic polymers were used either alone, in combination, or applied one over the other to 
impart delayed-release properties to the core drug pellets. It was demonstrated that dual 
delayed-release coating with two different enteric polymers-an inner acrylic coating followed 
by an outer cellulosic coating-yields the best product that provide all the desired 
physicochemical and drug dissolution characteristics
45
.  
Subramaniam et al (2010)., formulated and evaluated aspirin (75mg) delayed release 
tablet to provide a controlled and predictable release of Aspirin and which is used in the 
treatment of Coronary Thrombosis (heart disease) for Once in Day administration. The half 
life of Antiplatelet agent is 6 Hours which makes it suitable candidate for delayed release 
formulation. The present work aims to avoid degradation of drug in acidic environment of 
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stomach. So due to enteric coating drug releases in to the small intestine so that drug gets 
larger surface area for absorption. Micro crystalline cellulose, maize starch, cross carmilose 
Sodium is a disintegrent used to prepare a blend for direct compaction method
46
.  
Gohel et al (2005)., the present review outlines the importance of the functionality of 
the directly compressible adjuvants in the formulation of tablets. The co-processing is the 
most widely explored method for the preparation of directly compressible adjuvants because 
it is cost effective and can be prepared in-house based on the functionality required. Hence, 
the present review focuses on the properties of the co-processed directly compressible 
adjuvants available in the market
47
.  
Rajeshwar et al (2010)., developed gastroresistant drug delivery system for 
pantoprazole, is a proton pump inhibitor, this is alsoan acid labile drug, which can be 
degraded in the tomach. Therefore, the drug should be targeted to intestine; to bypass the 
stomach the gastroresistant double walled microspheric drug delivery system was adopted. 
The formulations were developed consisting of double wall. The primary wall composed of 
mucoadhesive polymer sodium CMC and a release controlling polymer sodium alginate. The 
second wall coating the primary microspheres was composed of eudragit S-100. The effect of 
polymer concentration onthe particle size, shape drug entrapment efficiency,mucoadhesive 
property, release study of core microspheres were evaluated
48
. 
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6. METHODOLOGY  
6.1. Preformulation studies  
6.1.1.Preparation of standard graph for pantoprazole sodium using acidic buffer (pH 
1.2)  
6.1.1.1. Determination of absorption maxima (λmax)  
100 mg of pantoprazole sodium sesquihydrate was weighed accurately and dissolved 
in 100 mL of pH 1.2 acidic buffer in 100 mL volumetric flask (stock solution). 2 mL was 
taken from the stock solution and transferred into 100 mL volumetric flask and diluted up to 
100 mL with pH 1.2 acidic buffer. The resulting solution was labeled as standard working 
Solution. 2 mL of the working solution was withdrawn and diluted up to 10 mL with pH 1.2 
acidic buffer in 10 mL volumetric flask. The spectrum of this solution was run in 200 to 400 
nm range in UV-visible spectrophotometer. The λ max of the pantoprazole sodium 
sesquihydrate was found to be 283 nm.  
6.1.1.2. Preparation of standard graph  
From above standard working solution, 1, 2, 3, 4, 5 and 6 mL was withdrawn and 
diluted up to 10 mL with pH 1.2 acidic buffer in 10 mL volumetric flask to get concentration 
of 2 μg, 4 μg, 6 μg, 8 μg, 10 μg and 12 μg respectively. The absorbance of each solution was 
measured by UV-visible spectrophotometer at 283 nm using the pH 1.2 acidic buffer as blank. 
6.1.2. Preparation of standard graph for pantoprazole sodium using phosphate  
buffer (pH 6.8)  
6.1.2.1. Determination of absorption maxima (λmax)  
100 mg of pantoprazole sodium sesquihydrate was weighed accurately and dissolved 
in 100 mL of pH 6.8 phosphate buffer in 100 mL volumetric flask (stock solution). 2 mL was 
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taken from the stock solution and transferred into 100 mL volumetric flask and diluted up to 
100 mL with pH 6.8 phosphate buffer. The resulting solution was labeled as standard working 
Solution. 2 mL of the working solution was withdrawn and diluted up to 10 mL with pH 6.8 
phosphate buffer in 10 mL volumetric flask. The spectrum of this solution was run in 200 to 
400 nm range in UV-visible spectrophotometer. The λ max of the pantoprazole sodium 
sesquihydrate was found to be 288 nm.  
6.1.2.2. Preparation of standard graph  
From standard working solution, 1, 2, 3, 4, 5 and 6 mL has withdrawn and diluted up 
to 10 mL with pH 6.8 phosphate buffer in 10 mL volumetric flask to get concentration of 2 μg, 
4 μg, 6 μg, 8 μg, 10 μg and 12 μg respectively. The absorbance of each solution was measured 
by UV-visible spectrophotometer at 288 nm using the phosphate buffer ( pH 6.8) as blank.  
6.1.3. FTIR spectra study  
This was carried out to find out the compatibility between the drug pantoprazole 
sodium sesquihydrate and the croscarmellos sodium, MCC, manito and other exicipients. 10 
mg of the sample and 400 mg of KBr were taken in a mortar and triturated. A small amount of 
the triturated sample was taken into a pellet maker and was compressed at10 Kg/cm2 using a 
hydraulic press. The pellet was kept on to the sample holder and 
scanned in Bruker FT-IR spectrophotometer. The spectra obtained were compared and 
interpreted for the functional group peaks.  
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6.2. Evaluation  
6.2.1. Precompression parameters  
6.2.1.1. Bulk density (Db)  
Accurately weighed granules were carefully transferred into graduated measuring 
cylinder. The granules bed was then made uniform and the volume occupied by the granules 
was noted as per the graduation marks on the cylinder as mL. It is expressed in gm/mL and is 
calculated using the following formula
49,50
.  
6.2.1.2. Tapped density (Dt)  
It is the ratio of total mass of granule to the tapped volume of granule. The graduated 
measuring cylinder containing accurately weighed granule was manually tapped for 50 times. 
Volume occupied by the granule was noted. It is expressed in gram/mL and is calculated by 
following formula
49,50
.  
6.2.1.3. Compressibility index (I) and Hausner’s ratio  
Carr’s index and Hausner’s ratio measure the propensity of granule to be compressed and the 
flow ability of granule. Carr’s index and Hausner’s ratio were calculated using following 
formula
49,50
.  
Dt – Db 
I =                       × 100 
Dt 
 
 
 
Hausner’s ratio     =      Dt /   Db 
 
Where, Dt – Tapped density of the powder 
 
Db – Bulk density of the powder 
 
 
Chapter 6                                                                                                                 Methodology 
 
Dept.of  Pharmaceutics                             47                          J.K.K.Nattaraja college of  Pharmacy 
 
 
6.2.1.4. Angle of repose (θ)  
The frictional forces in a loose powder can be measured by the angle of repose. This is 
the maximum angle possible between the surface of a pile of powder and the horizontal plane. 
Sufficient quantities of pantoprazole granules were passed through a funnel from a particular 
height (2 cm) onto a flat surface until it formed a heap, which touched the tip of the funnel. 
The height and radius of the heap were measured. The angle of repose was calculated using 
the formula
49,50
.  
Angle of repose (θ) = tan-1 (h/r)  
Where, h – Height of the pile in cm  
r – Radius of the pile  
6.3. Formulation studies  
6.3.1. Preparation of pantoprazole sodium tablets  
6.3.1.1. Preparation of powder blend  
Pantoprazole sodium sesquihydrate powder blend for tabletting were prepared by 
direct compression method. Specified quantity of pantoprazole, croscarmellos sodium, 
manitol, calcium phosphate, and MCC were weighed according to the formula (Table 3) and 
transferred in a mortar and pestle and mixed thoroughly. The powder was passed through 
sieve no 80 to obtain the granules. The specified quantity of magnesium stearate and talc were 
finally added and mixed for the compression of tablets.  
 
6.3.1.2. Preparation of pantoprazole sodium tablets  
An ideal mixture of granules were directly punched into tablets weighing about 200 
mg containing 40 mg of pantoprazole sodium sesquihydrate, using rotary tablet compression 
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machine (Riddhi 10 stn mini tablet press RDB4-10, Rimek, Ahmedabad, India), using 8 mm 
diameter concave punches. The different batches of pantoprazole tablets were collected and 
stored in air tight containers.  
Table 3. Composition of pantoprazole sodium enteric coated sodium tablets 
Composition F1 F2 F3 F4 F5 F6 F7 F8 F9 
Pantoprazole sodium  (mg) 40 40 40 40 40 40 40 40 40 
Croscarmellose sodium (mg) 2 4 6 2 4 6 2 4 6 
Microcrystalline cellulose(mg) 27 25 23 27 25 43 80 50 23 
Mannitol (mg) 50 75 100 40 85 80 43 50 75 
Dicalcium phosphate (mg) 75 50 25 85 40 25 75 50 50 
Talc (mg) 2 2 2 2 2 2 2 2 2 
Magnesium stearate (mg) 4 4 4 4 4 4 4 4 4 
Total weight (mg) 200 200 200 200 200 200 200 200 200 
 
 
6.4. Post compression parameters  
6.4.1. Hardness test  
The prepared tablets were subjected to hardness test
28,38
. It was carried out by using 
hardness tester and expressed in kg/cm2.  
6.4.2. Friability test  
The friabilit was determined using friabilator and expressed in percentage (%). 20 
tablets from each batch were weighed separately (Winitial) and placed in the friabilator, which 
was then operated for 100 revolutions at 25 rpm. The tablets were reweighed (Wfinal) and the 
percentage friability (F) was calculated for each batch by using the following formula
28,38
.  
(Winitial) - (Wfinal) 
F =                                       × 100 
(Winitial) 
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6.4.3. Weight variation test  
Twenty tablets were selected at random from the lot, weighed individually and the 
average weight was determined. The percent deviation of each tablets weight against the 
average weight was calculated
28,38
. The test requirements are met, if not more than two of the 
individual weights deviate from the average weight by more than 5% and none deviates more 
than 10%. IP limit for weight variation in case of tablets weighing more than 80 mg but less 
than 250 mg is ± 7.5 %.  
 
6.4.4. Drug content uniformity  
The prepared pantoprazole sodium sesquihydrate tablets were tested for their drug 
content. Three tablets of each formulation were weighed and finely powdered. About 40 mg 
equivalent of pantoprazole sodium sesquihydrate was accurately weighed and completely 
dissolved in pH 6.8 phosphate buffer and the solution was filtered. 1 mL of the filtrate was 
further diluted to 100 mL with pH 6.8 phosphate buffer. Absorbance of the resulting solution 
was measured by UV spectrophotometer at 288 nm
28
.  
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6.4.5 Disintegration time of Pantoprazole sodium core tablets  
Disintegration test was carried out using the tablet disintegration test apparatus 
(Servewell Instruments pvt. Ltd., Electrolab ED-2L, India) pH 6.8 phosphate buffer at 37 ± 
0.5 ºC was used as the disintegration media and the time in second taken for complete 
disintegration of the tablet  
6.5 Coating of compressed pantoprazole sodium tablets  
6.5.1. Preparation of enteric coating solution  
The enteric coating solution was prepared by simple solution method. It was 
prepared by 6% w/w and 8% W/W of Eudragit L100 ( E1 and E2)or cellulose acetate 
phthalate (C1 and C2) as an enteric polymer, PEG 1.5% w/w as plasticizer and acetone and 
isopropyl acetone was used as solvent. Diethyl phthalate was added and made up the volume 
with rest of the solvent mixture; this mixture was constantly stirred for 1h with paddle 
mechanical stirrer at the rate of 1000 rpm and the stirred coating solution was again filtered 
through muslin cloth, a coating solution was obtained38,42. 
Table 4. Composition of coating solution 
Ingredients Quantity (%) 
Cellulose  acetate  phthalate/     
Eudragit L100 6.0 / 8.0 
PEG 1.5 
Acetone 59.4 
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6.5.2. Enteric coating of pantoprazole sodium compressed tablets by  
dipping method  
The compressed tablets were coated with enteric coating polymer (Eudragit L100 or 
cellulose acetate phthalate) solution by dipping method. Desired tablet coating continued the 
dipping and weight gain was achieved. The coated tablets were studied for its weight 
variation, thickness, uniformity of drug content and in vitro dissolution study
38,42
.  
 
6.5.3. Physicochemical evaluation of coating films  
The same polymer solution was used to prepare the polymeric films and was 
subjected for film thickness, film solubility.  
The polymeric films were prepared by casting the acetone with PEG the polymer 
solution was poured on the glass plate. The film was dried for 24 h at room temperature under 
a special cover with reduced solvent evaporation to obtained smooth homogenous films. The 
dried films were cut in to 1cm
2
 area the prepared polymeric film was studied for film 
thickness, and film solubility. The thickness of dried films was determined by thickness 
Digital micrometer. The film solubility was studied with pH 1.2 and pH 6.8. The 1×1 cm
2
 
coating film was selected, weighed and transferred in a beaker containing 20 mL of specified 
pH medium, which was mixed in a magnetic stirrer for 1 h at 37 ± 1°C and finally film 
solubility was examined.  
6.5.4 In vitro drug release studies  
USP dissolution apparatus type II (Electrolab TDT-08L,Mumbai,India) was employed 
to study the in vitro drug release from various formulations prepared. The dissolution 
medium used was 900 mL of acidic buffer of pH 1.2 for 2 h and phosphate buffer of pH 6.8 
Chapter 6                                                                                                                 Methodology 
 
Dept.of  Pharmaceutics                             52                          J.K.K.Nattaraja college of  
Pharmacy 
 
 
for 1 hrs. The tablet was kept in to the basket. The temperature was maintained at 37 ± 0.5°C 
and the stirring rate was 100 rpm. Samples were withdrawn at regular time intervals and the 
same volume was replaced with fresh dissolution medium. The samples were measured by 
UV spectrophotometer at 283 nm (pH 1.2) and at 288 nm (pH 6.8) against a blank. The 
release studies were conducted in triplicate and the mean values were plotted versus time
28
. 
  
6.6. Stability studies  
Stability studies were performed as per the ICH guidelines. Selected formulations of 
Pantoprazole sodium tablet were sealed in aluminum foil cover and stored at (40 ± 2 °C / 75 
± 5 % R.H) for a period of 3 months. Samples from each formulation which are kept for 
examination were withdrawn at definite time intervals. The withdrawn samples were 
evaluated for physical appearance, hardness, drug content 
29
. 
 
 LIST OF CHEMICALS USED 
 
SL. 
 
No. 
 
Materials 
 
Manufacturer / Supplier 
1 Acetone SD Pharma, Mumbai, India 
2 Calcium phosphate Fine Chem Industries, India 
3 Disodium hydrogen phosphate Fine Chem Industries, India 
4 Potassium dihydrogen phosphate Cipla Pharma, Mumbai, India 
5 Cellulose acetate phthalate SD Pharma, Mumbai, India 
6 Micro crystalline cellulose Cipla Pharma, Mumbai, India 
7 Mannitol Signet Chemical Corporation 
8 Croscarmellose sodium SD Chemical Corporation 
9 Pantoprazole sodium sesquihydrate Signet Chemical Corporation 
10 Talc Spectrochem Pvt. Ltd. Mumbai. 
11 Magnesium stearate Spectrochem Pvt. Ltd. Mumbai. 
12 Eudragit L-100 Sd fine Chem. Ltd., Mumbai, India. 
 
13 
 
Potassium dihydrogen Phosphate 
Spectrum reagent and chemicals Pvt. 
 
Ltd., India. 
 
14 
 
Hydrochloric acid 
Swastik Pharmaceuticals, Mumbai, 
 
India. 
 
 
 
 
 
 
 
SL. 
 
NO 
 
Equipment 
 
Manufacturer / Supplier 
1 Rotary tablet punching machine Ridhi Pharma machinery, Ahmedabad, India 
2 UV Spectrophotometer Shimadzu 1800, Japan 
3 Digital Electronic Balance Citizon, India. 
4 Monsanto Hardness tester Labtech, India 
5 Friability apparatus Ketan, Koshish Industries, India 
6 Digital pH meter Hanna, India 
7 Vernier calipers Mitutoyo. Japan 
8 Disintegration test apparatus Electrolab ED-2L,Servewell Industries, India 
9 Dissolution test apparatus Electrolab TDT-08L Servewell Industries, India 
10 FTIR Spectrophotometer Bruker,Japan. 
11 Hot air oven Servewell Industries, India 
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7. RESULTS AND DISCUSSIONS 
Present study was done on enteric coating tablets with different formulation F1 to F9. 
Pantoprazole sodium sesquihydrate were prepared by direct compression method using 
different concentration of, microcrystalline cellulose, mannitol, dicalcium phosphate, 
croscarmellose sodium, magnesium stearate and talc, CAP and Eudragit L100 were used as 
enteric coating polymer, which prevent drug form gastric pH and release in intestinal pH.  
7.1. Preformulation studies  
7.1.1. Preparation of standard graphs  
Standard graph for the drug pantoprazole sodium was done separately in pH 1.2 acidic 
buffer and pH 6.8 phosphate buffer. Table 5 and 6 show the concentrations of pantoprazole 
sodium in pH 1.2 acidic and pH 6.8 phosphate buffers and the respective absorbance. The 
Figure 4 and 5 show the calibration curves of pantoprazole sodium in pH 1.2 acidic buffer and 
pH 6.8 phosphate buffer respectively. 
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y = 0.0371x + 0.0011 
R² = 0.9969 
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Table 5. Calibration data of pantoprazole sodium in 0.1N HCl (pH 1.2) 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Standard graph of pantoprazole sodium in 0.1N HCl (pH 1.2) 
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SL. NO.   Concentration  
(mg /mL)  
Absorbance* 
(nm) 
1  0 0 
2  2 0.082+0.0005 
3  4 0.145+0.0015 
4  6 0.231+0.0101 
5  8 0.289+0.0023 
6  10 0.361+0.0025 
7  12 0.459+0.0047 
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y = 0.038x + 0.0 
R² = 0.997 
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Table 6. Calibration data of pantoprazole sodium in phosphate buffer (pH 6.8) 
 
 
 
SL. NO. 
Concentration 
(mg /mL) 
 
Absorbance*(nm) 
1 0 0 
2 2 0.085+0.0040 
3 4 0.149+0.0036 
4 6 0.243+0.0015 
5 8 0.305+0.0075 
6 10 0.373+0.0051 
7 12 0.468+0.0020 
*Mean+SD, n = 3 
 
 
 
 
 
 
 
Figure 5. Standard graph of pantoprazole sodium in phosphate buffer (pH 6.8) 
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7.1.2. FTIR spectral study  
FT-IR spectroscopy study was carried out separately to find out the compatibility 
between the drug pantoprazole and Microcrystalline cellulose, mannitol, dicalcium 
phosphate, croscarmellose sodium. The FT-IR was performed for drug, polymer and the 
physical mixture of drug-polymer. The spectral obtained from FT-IR spectroscopy studies 
shows in Table 7 and Figures 6-9  
The peaks obtained in the spectra of drug and polymers mixtures correlates with each 
other. This indicates that the drug was compatible with the formulation components. IR 
studies indicated no interaction between drug and polymers.  
 
Figure 6. FTIR Spectrum of pantoprazole sodium 
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Figure 7. FTIR Spectrum of physical mixture of pantoprazole sodium with mannitol 
 
 
Figure 8. FTIR Spectrum of physical mixture of pantoprazole sodium with  
dicalcium phosphate 
 
Figure 9. FTIR Spectrum of physical mixture of pantoprazole sodium with Dicalcium 
phosphate and mannitol 
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The standard band frequency of the pantoprazol sodium is show in the Table 7.  
 
Table 7.  Standard band frequency of  Pantoprazole Sodium 
 
Wave number 
in cm
-1
 
Characteristic 
1900 C=H 
1650 - 1580 N-H bending 
1600 - 1400 Aromatic C=C stretching 
1400 - 1000 C-N bending 
1373 C-F 
1049 S=O 
The spectra obtained from the physical mixture show that all the principle peaks are at 
or around the requisite wave number of pure drug. Thus it may be inferred that there was no 
chemical interaction between drug and polymer and the purity and integrity of drug was 
maintained in the physical mixtures. 
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7.2. Evaluations  
7.2.1.Precompression parameters  
The prepared pantoprazole powder blend for tabletting was prepared by direct 
compression method. The prepared pantoprazole powder blend were evaluated angle of 
repose, bulk density, tapped density, Hausner’s ratio and compressibility index as given on 
Table 8.  
The bulk densities of the granules were found to be in the range of 0.306 ± 0.03 to 
0.384. ± 0.04 gm/mL, while the tapped densities were ranged between 0.313 ± 0.04 to 0.429 
± 0.05 gm/mL. The flow characteristics of the granules were assessed by determining their 
angle of repose and Carr’s Index. The values of compressibility (5.74 ± 0.13 to 10.48 ± 
0.20%) signify good flowability. The angle of repose of all formulation was less than 30 º 
(25.79 ± 0.24 to 29.52 ± 0.14) also indicate the good flowability of the prepared granules. 
7.2.2 Formulation studies  
7.2.2.1. Preparation of of pantoprazole sodium tablets  
The pantoprazole sodium sesquihydrate tablets were prepared by direct compression 
method A total of nine formulations (F1-F9) by using a rotary tablet compression machine (8 
mm diameter, Riddhi 10 stn mini tablet press RDB4-10, Rimek, Ahmedabad, India). 
Compositions of the pantoprazole sodium sesquihydrate tablets are shown in Table 3.  
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Table  8  Pre compression parameters of pantoprazole sodium 
 
 
 
Formulation 
Code 
 
Parameter 
Bulk density 
(gm/mL) * 
Tapped 
density 
(gm/mL) * 
Carr’s Index 
(%)* 
Hausner’s 
ratio* 
Angle of repose 
(Ɵ)* 
 
F1 
 
0.357±0.03 
 
0.384±0.05 
 
7.03±0.09 
 
1.075±0.04 
 
28.31±0.26 
 
F2 
 
0.312±0.04 
 
0.335±0.02 
 
6.86±0.15 
 
1.073±0.05 
 
27.20±0.14 
 
F3 
 
0.306±0.03 
 
0.326±0.03 
 
6.13±0.12 
 
1.065±0.02 
 
29.13±0.34 
 
F4 
 
0.312±0.03 
 
0.334±0.06 
 
6.58±0.14 
 
1.070±0.06 
 
26.13±0.26 
 
F5 
 
0.306±0.03 
 
0.334±0.05 
 
8.38±0.17 
 
1.091±0.08 
 
26.78±0.18 
 
F6 
 
0.384±0.04 
 
0.429±0.05 
 
10.48±0.20 
 
1.117±0.07 
 
25.79±0.24 
 
F7 
 
0.358±0.05 
 
0.385±0.04 
 
7.01±0.13 
 
1.075±0.03 
 
29.52±0.14 
 
F8 
 
0.286±0.05 
 
0.313±0.04 
 
8.62±0.07 
 
1.094±0.03 
 
26.95 ±0.15 
 
F9 
 
0.348±0.08 
 
0.328±0.05 
 
5.74±0.13 
 
1.06±0.08 
 
26.13±0.26 
*Mean  ± SD  n=3 
 
 
 
7.2.2.2. Post compression parameters of pantoprazole sodium core tablet  
The pantoprazole tablets were prepared by direct compression method and were 
evaluated for their hardness, weight variation, content uniformity, friability and in vitro drug 
release (Table 9).  
Hardness has to be controlled to ensure that the product is firm enough to withand 
handling without breaking or crumbling and not so hard that the disintegration time is unduly 
prolonged. The average hardness of the tablets to be in range was found within 4.93 ± 0.15 to 
6.20 ± 0.35 Kg / cm2. Friability value which also affected by the hardness value of tablets 
should be in the range 1% limits, which is the usual friability range of tablets. The friability 
of the prepared tablets was found less than 1% w/w. The drug content uniformity of 
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pantoprazole sodium present in tablets formulation ranged from 96.28 ± 0.15to 100.34 ± 
0.13%. The average weight found 198 ± 0.15 to 206 ± 0.24 mg. Disintegration time varied 
between 11.48 ± 0.15 to 5.38 ± 0.23, hence all shows favorable result. 
 
 
 
Table 9 .  Post compression parameters of  pantoprazole  sodium core 
tablets 
 
 
 
 
Formulation 
 
Code 
Parameter 
Hardness 
 
2 
(Kg/cm   )* 
Friability 
 
(%)* 
Weight 
 
variation 
 
(mg) * 
Drug content 
 
(%)* 
Disintegration 
 
time(min) * 
F1 5.80 ± 0.12 0.69 ± 0.015 199 ± 0.12 96.28 ± 0.15 10.6± 0.62 
F2 5.56 ± 0.24 0.51 ± 0.017 206 ± 0.24 97.62 ± 0.27 8.26± 0.56 
F3 5.83 ± 0.08 0.48 ± 0.014 201 ± 0.17 99.51 ± 0.36 5.38± 0.23 
F4 4.93 ± 0.15 0.64 ± 0.015 208 ± 0.20 98.17 ± 0.16 11.48± 0.15 
F5 5.73 ± 0.25 0.71 ± 0.016 203 ± 0.16 98.92 ± 0.42 9.32± 0.18 
F6 5.12 ± 0.34 0.68 ± 0.026 206 ± 0.14 100.34 ± 0.13 6.13± 0.25 
F7 5.66 ± 0.17 0.54 ± 0.026 199 ± 0.22 98.50 ± 0.48 10.54± 0.43 
F8 6.20 ± 0.35 0.49 ± 0.025 204 ± 0.18 98.41 ± 0.34 9.12± 0.71 
F9 5.60 ± 0.24 0.42 ± 0.018 198 ± 0.15 99.08 ± 0.35 6.02± 0.21 
* Mean ± SD, n=3 
 
 
7.2.2.3. Physicochemical evaluation of coating films  
Physicochemical evaluation of cellulose acetate phthalate, Eudragit L100 and were 
studied for different parameters such as film thickness, film weight and film solubility. The 
enteric polymer cellulose acetate phthalate, Eudragit L100 were found to be completely 
soluble in pH6.8 and insoluble in pH1.2 (Table 10).  
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7.2.2.4. Physicochemical evaluation of pantoprazole sodium enteric coated tablets  
The tablets which shows most satisfactory result in disintegration, and drug content 
parameters( F3 and F9) coated by dip coating method. The results of physicochemical 
evaluation of prepared coated tablets are shown in Table 11. The weight variation was found 
to be between 0.211 ± 0.024 % to 214 ± 0.021 mg. The drug content was found to be between 
93.47 ± 0.23% to 98.45 ± 0.12%. The hardness was found to be from 5.2 ± 0.11 to 6.5 ± 0.15 
Kg / cm2. 
 
Table 10 Physicochemical evaluation of different polymer coating films 
 
 
 
 
Polymer 
Parameter 
Film solubility Film thickness 
(mm) * pH 1.2 pH 6.8 
 
CAP 
 
Insoluble 
 
Soluble 
 
0.21 ± 0.07 
 
Eudragit L 100 
 
Insoluble 
 
Soluble 
 
0.24 ± 0.08 
*Mean+SD, n = 3 
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Table 11. Physicochemical evaluation parameters of enteric coated tablets 
  
 
 
 
 
 
Polymer 
 
 
Batch 
Code 
Parameter 
Weight 
Variation 
(mg) * 
Hardness 
Kg/cm
2
* 
Drug content 
(%)* 
 
 
 
 
CAP 
C1F3 211 ± 0.035 6.5 ± 0.15 96.75 ± 0.14 
C2F3 214 ± 0.016 5.9 ± 0.24 93.65 ± 0.35 
C1F9 212 ± 0.006 5.4 ± 0.09 94.45 ± 0.26 
C2F9 210 ± 0.024 6.3 ± 0.14 98.54 ± 0.12 
 
 
 
Eudragit 
L 100 
E1F3 214 ± 0.021 5.5 ± 0.16 93.47 ± 0.23 
E2F3 213 ± 0.012 6.0 ± 0.06 94.56 ± 0.14 
E1F9 215 ± 0.015 6.5 ± 0.31 98.27 ± 0.45 
E2F9 211 ± 0.024 5.7 ± 0.20 96.35 ± 0.12 
*Mean+SD, n = 3 
 
 
7.2.2.5. In vitro drug release studies of enteric coated tablets  
The in vitro release of pantoprazole sodium from the prepared tablets was studied in 
ph 1.2 for 2 h and in phosphate buffer pH 6.8 for 1 h. In vitro dissolution studies were 
performed using USP Type II rotating paddle dissolution apparatus (Electrolab TDT-08L, 
India) by using 1.2 N HCl and phosphate buffer (pH 6.8) as a dissolution medium. 
Formulation which shows most satisfactory result is C2F9, where drug release started after 2 
hrs, and released maximum 99.72 by 3 hrs. Remaining were respectively, released started and 
reached maximum, CIF3-90 min and 96.42 in 3 hrs, C2F3-2 hrs and 94.59 in 195 min, E1F3-
90 min and 98.15 in 165 min, E2F3-105 min and 97.54 in 3 hrs, C1F9-90 min and 99.79 in 
165 min, EIF9-90 min and 97.97 in 165 min, E2F9-2 hrs and 97.39 in 3 hrs. The cumulative 
percentage releases of pantoprazole sodium from the tablets were shown in Table 12-19 and 
Figure 11-12. 
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Table 12. In vitro drug release of pantoprazole sodium (C1F3) 
 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
Conc. 
in 900 
mL 
(mg /mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug 
released * 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0.024 0.6469 5.822 0 0 5.822 14.62+0.52 
120 0.06 1.6172 14.555 0.0064 0.0064 14.561 36.58+0.40 
135 0.091 2.3884 21.496 0.0161 0.0226 21.518 54.05+0.90 
150 0.121 3.1758 28.582 0.0238 0.0465 28.629 71.91+0.39 
165 0.142 3.7270 33.543 0.0317 0.0782 33.621 84.46+0.17 
180 0.162 4.2519 38.267 0.0372 0.1155 38.383 96.42+0.40 
* Mean+SD, n = 3 
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Table  13. In vitro drug release of pantoprazole sodium (C2F3) 
 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug released 
* 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
135 0.019 0.4986 4.488 0 0 4.488 11.27 ±0.90 
150 0.082 2.1522 19.370 0.0049 0.0049 19.375 48.67+0.27 
165 0.122 3.2021 28.818 0.0215 0.0265 28.845 72.46+0.18 
180 0.149 3.9107 35.196 0.0320 0.0585 35.255 88.56+0.42 
195 0.159 4.1732 37.559 0.0391 0.0976 37.656 94.59+0.70 
* Mean+SD, n = 3 
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Table 14. In vitro drug release of pantoprazole sodium (E1F3) 
 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug released 
* 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0.041 1.1051 9.946 0 0 9.946 24.98+0.34 
120 0.071 1.9137 17.223 0.0110 0.0110 17.234 43.29+0.62 
135 0.116 3.0446 27.401 0.0191 0.0301 27.431 68.91+0.72 
150 0.137 3.5958 32.362 0.0304 0.0606 32.422 81.44+0.58 
165 0.165 4.3307 38.976 0.0359 0.0965 39.072 98.15+0.40 
* Mean+SD, n = 3 
 
Table  15. In vitro drug release of  pantoprazole sodium (E2F3) 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage drug 
released 
* 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0.02 0.5390 4.851 0 0 4.851 12.18+0.82 
135 0.07 1.8372 16.535 0.0053 0.0053 16.540 41.55+0.66 
150 0.116 3.0446 27.401 0.0183 0.0237 27.425 68.89+0.72 
165 0.142 3.7270 33.543 0.0304 0.0542 33.597 84.39+0.48 
180 0.164 4.3044 38.740 0.0372 0.0914 38.831 97.54+0.70 
* Mean+SD, n = 3 
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Table 16. In vitro drug release of pantoprazole sodium (C1F9) 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug released 
* 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0.04 1.0781 9.703 0 0 9.703 24.48+0.18 
120 0.079 2.1293 19.164 0.0107 0.0107 19.175 48.38+0.67 
135 0.121 3.1758 28.582 0.0212 0.0320 28.614 72.20+0.58 
150 0.15 3.9370 35.433 0.0317 0.0638 35.496 89.56+0.42 
165 0.167 4.3832 39.448 0.0393 0.1032 39.552 99.79+0.70 
* Mean+SD, n = 3 
Table 17. In vitro drug release of pantoprazole sodium (C2F9) 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug released 
* 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0 0 0 0 0 0 0 
135 0.054 1.417 12.755 0 0 12.755 32.18+0.34 
150 0.098 2.572 23.149 0.0141 0.0141 23.163 58.44+0.58 
165 0.139 3.648 32.834 0.0257 0.0398 32.874 82.94+0.18 
180 0.167 0.038 0.043 39.448 0.0364 0.076 99.72+0.46 
* Mean+SD, n = 3 
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Table 18. In vitro drug release of pantoprazole sodium (E1F9) 
 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug released 
* 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0.03 0.8086 7.277 0 0 7.277 18.36+0.42 
120 0.063 1.6981 15.283 0.0080 0.0080 15.291 38.58+0.22 
135 0.104 2.7296 24.566 0.0169 0.0250 24.592 62.05+0.58 
150 0.15 3.9370 35.433 0.0272 0.0523 35.485 89.53+0.39 
165 0.164 4.3044 38.740 0.0393 0.0917 38.831 97.97+0.48 
* Mean+SD, n = 3 
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Table  19. In vitro drug release of pantoprazole sodium (E2F9) 
 
Time 
(min) 
 
 
Absorbance 
 
Conc. 
(µg/mL) 
 
Conc. 
in 900 mL 
(mg / mL) 
 
 
Loss 
 
Cumulative 
loss 
 
Cumulative 
drug released 
Cumulative 
percentage 
drug 
released * 
0 0 0 0 0 0 0 0 
15 0 0 0 0 0 0 0 
30 0 0 0 0 0 0 0 
45 0 0 0 0 0 0 0 
60 0 0 0 0 0 0 0 
75 0 0 0 0 0 0 0 
90 0 0 0 0 0 0 0 
105 0 0 0 0 0 0 0 
120 0.027 0.7277 6.549 0 0 6.549 16.52+0.16 
135 0.071 1.8635 16.771 0.0072 0.0072 16.778 42.33+0.35 
150 0.118 3.0971 27.874 0.0186 0.0259 27.899 70.39+0.63 
165 0.149 3.9107 35.196 0.0309 0.0568 35.253 88.95+0.44 
180 0.163 0.0381 0.042 38.503 0.0391 0.095 97.39+0.61 
* Mean+SD, n = 3 
 
Figure 11. In vitro drug release of pantoprazole sodium (C1F3 to E2F3) 
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Figure 12. In vitro drug release of pantoprazole sodium (C1F9 to E2F9) 
              
7.2.2.6. Stability studies  
Stability of a drug in a dosage form at different environmental conditions is important 
as it determines the expiry date of that particular formulation. Changes in the physical 
appearance, color, odor, taste or texture of the formulation indicate the drug instability. 
Among the three enteric coated Formulation, Formulation C2F9 was selected for stability 
studies based on the physicochemical characterization of coating films and release 
characteristics.  
The stability studies were carried out at 40 ± 2 °C with 75 ± 5%% RH which shown in 
Table 20. There were no significant changes in their physical appearance, average weight of 
tablets and hardness. It was observed that the initial drug content and the drug contents of the 
samples analyzed after 1,2,3 month of storage were similar. The release profile also not 
showed any significant changes indicating that there were no significant changes in the physical 
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as well as chemical characteristics of the formulation. Hence, it can be concluded from the 
results that the developed tablets were stable and retain their pharmaceutical properties over a 
period of 3 month. 
Table 20.Stability studies of cellulose acetate phthalate coated tablet  
formulation C2F9 
 
 
Evaluation 
parameters 
Observation in month 
Initial 1
st  
month 2
nd  
month 3
rd  
month 
 
Physical Appearance 
white color 
tablets 
 
No   change 
 
No change 
 
No change 
Hardness  (Kg / cm
2
) * 
 
6.3 ± 0.14 6.2 ± 0.56 6.2 ± 0.64 6.2 ± 0.26 
 
Drug Content (%)* 
 
98.54 ± 0.12 98.36 ± 0.52 98.16 ± 0.36 98.07 ± 0.28 
 
*Mean ± SD, n=3 
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8. SUMMARY & CONCLUSION 
SUMMARY  
The aim of the present study was to formulate and evaluate of enteric coated 
pantoprazole sodium sesquihydrate tablets by using manotol, dicalcium phosphate, 
microcrystalline cellulose, crossrmelose sodium, magnesium starate and talc.  
FT-IR study was carried out to check any possible interactions between the drug and the 
excipients manotol, dicalcium phosphate, microcrystalline cellulose, crosscarmelose sodium,  
Pantoprazole sodium sesquihydrate were prepared by direct compression method using 
different concentration of, Avicel PH (MCC) as filler, mannitol and dicalcium phosphate as 
diluents, croscarmellose sodium as disintegrating agents, magnesium stearate and talc was 
used as a glidant and lubricant respectively. The granules were evaluated for the 
precompression parameters like angle of repose, bulk density, tapped density and 
compressibility index. The flow characteristics of the granules were assessed by determining 
their angle of repose and Carr’s Index. The values of compressibility index and angle of 
repose signify good flowability of the granules for all the batches. This shows that the 
granules had smooth flow properties ensuring homogenous filling of the die cavity during the 
compression (punching) of tablets.  
Coating has been done for the selected formulation from the proposed formulation 1- 
9. Coating materials like CAP and Eudragit L100 with the difference concentration.  
The in vitro dissolution studies were carried out for compressed and coated tablets using USP 
dissolution apparatus type II. The cumulative percentage of drug release from the tablets 
varied and depends on the type of polymer used and its concentration. 
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Formulation 3 and formulation 9 was selected for the coating. CAP and Eudragit L 
100 was used for the coating polimer. In this present study coating material was used with 6 
and 8 percentage on the above mentioned formulation.  
The stability study indicated that the prepared formulation was stable retained their 
pharmaceutical properties at room temperature and 40°C/75% RH over a period of 1 month. 
The coated tablets did not release the drug in hostile acidic environment (pH 1.2) due to 
protective polymer coating and released the drug in the intestinal environment (pH 6.8).  
Formulation 9, coated with 8% CAP was found to be best formulation, based on release time 
of the drug in the intestine. 
CONCLUSION 
An attempt was made in this research work to formulate an oral enteric coating 
pantoprazole sodium tablet and evaluate it. An ulcer is the disease caused by an imbalance 
between aggressive and defensive factors. Ulcer sarecrater-like sores which form in the lining 
of the stomach, just below the stomach at the beginning of the small intestine in the 
duodenum.Pantoprazole is a substituted benzimidazole derivative that targets gastric acid 
proton pumps, the final common pathway for gastric acid secretion. The drug covalently 
binding to the proton pumps, causing prolonged inhibition of gastric acid secretion.The 
stability of pantoprazole is depending on pH and it rapidly degrades in acid medium of the 
stomach,but stable in alkaline conditions. Therefore, pantoprazole should be delivered into 
the intestine. Hence, an attempt was made to formulate an enteric coated drug delivery 
system for pantoprazole by using various enteric coating polymers.  
From the reproducible results obtained from the executed experiments it can be 
concluded that CAP and Eudragit L 100 can be used as enteric coated polymer. Both the 
polymer can protect the drug from the acid environment that is in gastric pH and release the 
drug when it’s reached in intestinal pH.  
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In this present research work, both the polymer have been used as an enteric coating 
polymer, with the best formulation. CAP and EudragitL100 have been used 6% and 8% with 
the best formulation. From the dissolution studies it was observed that, the enteric coated 
both polymer was intact for 2 hours in pH 1.2 buffer. The formulation which is said to the 
best formulation is C2F9, which is formulation no. 9 and coated with 8% CAP. 
Therefore thestudyprovedthat the pantoprazole enteric coated tablets can be used for 
ulcer and GERD disease.  
 
Hence, formulation of pantoprazole as an enteric coated tablet may solve the stability 
problem of drug in the stomach and release the drug in the intestine. After satisfied pre-
compression and post compression result the of core tablets, tablets were coated with suitable 
coating material to develop the dosage form which is to overcome the drug degradation by 
the gastric enzymes as well as the acidic environment of the stomach. 
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